Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial is a research paper published in Clinical and Molecular Hepatology (2024). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01CA237327
National Cancer Institute
Grant: P50CA217674
National Cancer Institute
Grant: P30CA016672
Korea University
Grant: 20024893
National Research Foundation of Korea
Grant: 2023R1A2C10073311212982036810102
National Institutes of Health
Grant: 5R01CA237327-05
PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATION
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5P50CA217674-04
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
The Korean Association for the Study of the Liver
MD Anderson
Ministry of Science and ICT
Ministry of Trade, Industry and Energy
NIH HHS
The Korean Liver Foundation
National Institutes of Health
Fields of Study
MeSH Terms
Keywords